Teva Pharmaceutical Industries Limited or Ionis Pharmaceuticals, Inc.: Who Invests More in Innovation?

Teva vs. Ionis: A Decade of R&D Investment

__timestampIonis Pharmaceuticals, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20142417510001488000000
Thursday, January 1, 20153222920001525000000
Friday, January 1, 20163443200002111000000
Sunday, January 1, 20173746440001848000000
Monday, January 1, 20184146040001213000000
Tuesday, January 1, 20194660000001010000000
Wednesday, January 1, 2020535000000997000000
Friday, January 1, 2021643000000967000000
Saturday, January 1, 2022833000000838000000
Sunday, January 1, 2023899625000953000000
Monday, January 1, 2024901530000998000000
Loading chart...

Unlocking the unknown

Innovation Investment: A Tale of Two Pharmaceutical Giants

In the competitive world of pharmaceuticals, innovation is key to staying ahead. Over the past decade, Ionis Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Limited have been at the forefront of this race. From 2014 to 2023, Teva consistently outspent Ionis in research and development, with an average annual investment nearly 2.5 times higher. However, Ionis has shown remarkable growth, increasing its R&D spending by approximately 272% over this period. In 2023, Ionis reached a milestone, investing nearly 90% of Teva's R&D budget. This trend highlights Ionis's commitment to innovation, potentially reshaping the competitive landscape. As these companies continue to invest in groundbreaking research, the future of pharmaceuticals looks promising, with new treatments and technologies on the horizon.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025